Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa-Science-Chemical Encyclopedia-lookchem

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from Agalsidase Beta (cas 104138-64-9) to agalsidase alfa
Add time:08/03/2019 Source:sciencedirect.com

BackgroundFabry disease is an X-linked inherited lysosomal storage disease that can be treated with the enzymes of Agalsidase Beta (cas 104138-64-9) (Fabrazyme) and agalsidase alfa (Replagal). Since June 2009, viral contamination of Genzyme's production facility has resulted in a worldwide shortage of agalsidase beta, leading to the switch to agalsidase alfa for patients with Fabry disease in Taiwan.

We also recommend Trading Suppliers and Manufacturers of Agalsidase Beta (cas 104138-64-9). Pls Click Website Link as below: cas 104138-64-9 suppliers

Prev:Non-clinical evaluation of JR-051 as a biosimilar to Agalsidase Beta (cas 104138-64-9) for the treatment of Fabry disease
Next: Sensitive determination of enoxacin by its enhancement effect on the fluorescence of terbium(III)–sodium dodecylbenzene sulfonate and its luminescence mechanism)

Click to view details

Encyclopedia